Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

https://www.soho2019.com/

 

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
Avatar

BCL-2 Inhibition in AML: High Effectiveness of Combination Therapy - Overview of Trials Combining Venetoclax and Targeted Agents (IDH, FLT3, MDM2 Inhibitors)

By Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019) FEATURING Marina Konopleva
By Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019) FEATURING Marina Konopleva
125 views
November 5, 2019
0 Comments
Login to view comments. Click here to Login

Featured Video

15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay

Featured Video

06:51
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…

Feat. D. Tremblay
Breakfast With The Expert
16:04
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Optimizing Care for the Older Adolescent and Young Adult: Health Car…

Feat. N. Boissel
14:32
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

ALL Therapy for the Young Adults: Adoption of Pediatric Regimen, MRD…

Feat. W. Stock
39:21
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

BCL-2 Inhibition in AML: High Effectiveness of Combination Therapy -…

Feat. M. Konopleva
12:03
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Histology of the Marginal Zone Lymphoma

Feat. E. Zucca
21:31
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Marginal Zone Lymphoma: Role of PET, Antibiotic Therapy in Non-GI MA…

Feat. E. Zucca